Nifty
:
24570.65
Sensex
:
78499.17
-65.35 (-0.27%)
-455.59 (-0.58%)
Nifty
Sensex
:
:
24570.65
78499.17
-65.35 (-0.27%)
-455.59 (-0.58%)

Suven Life Sciences Ltd.

Pharmaceuticals & Drugs - API

Rating :
62/99

BSE: 530239 | NSE: SUVEN

NSE BSE
318.40
07-Aug-2026
  • Open
  • High
  • Low
  • Previous Close
  •  313
  •  324.25
  •  312
  •  317.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  486776
  •  155132106.8
  •  371
  •  124.11

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 8,991.14
  • N/A
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 8,653.69
  • N/A
  • 16.14

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 70.08%
  • 2.37%
  • 21.37%
  • FII
  • DII
  • Others
  • 0.56%
  • 0.01%
  • 5.61%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -35.19
  • -9.70
  • -15.27

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 18.39
  • 17.33

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 17.77
  • 38.03

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.90
  • 15.62
  • 14.98

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -9.26
  • -17.28
  • -21.50

Earnings Forecasts:

(Updated: 08-08-2026)
Description
2026
2027
2028
2029
Adj EPS
40
23
-
-
P/E Ratio
7.96
13.84
-
-
Revenue
-
-
-
-
EBITDA
-
-
-
-
Net Income
-
-
-
-
ROA
-
-
-
-
P/B Ratio
-
-
-
-
ROE
-
-
-
-
FCFF
-
-
-
-
FCFF Yield
-
-
-
-
Net Debt
-
-
-
-
BVPS
-
-
-
-

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Net Sales
3.57
1.87
90.91%
1.52
1.47
3.40%
2.81
1.61
74.53%
0.92
2.57
-64.20%
Expenses
136.07
52.61
158.64%
52.15
45.29
15.15%
106.16
40.82
160.07%
80.69
54.78
47.30%
EBITDA
-132.50
-50.75
-
-50.63
-43.82
-
-103.35
-39.21
-
-79.77
-52.21
-
EBIDTM
-3,715.76%
-2,718.16%
-3,331.12%
-2,987.12%
-3,679.25%
-2,435.22%
-8,680.20%
-2,029.07%
Other Income
7.52
0.60
1,153.33%
6.78
1.22
455.74%
2.77
1.63
69.94%
3.78
4.04
-6.44%
Interest
0.48
0.00
0
0.16
0.00
0
0.00
0.01
-100.00%
0.00
0.02
-100.00%
Depreciation
2.16
1.37
57.66%
1.58
1.35
17.04%
1.35
1.53
-11.76%
1.32
1.46
-9.59%
PBT
-127.61
-51.52
-
-45.59
-43.95
-
-101.92
-39.12
-
-77.31
-49.64
-
Tax
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PAT
-127.61
-51.52
-
-45.59
-43.95
-
-101.92
-39.12
-
-77.31
-49.64
-
PATM
-3,578.55%
-2,759.29%
-2,999.67%
-2,995.57%
-3,628.41%
-2,429.69%
-8,412.40%
-1,929.38%
EPS
-4.83
-2.36
-
-1.73
-2.02
-
-4.48
-1.79
-
-3.40
-2.28
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
8.82
7.11
6.66
11.69
13.54
11.84
13.48
14.41
285.67
625.26
543.53
Net Sales Growth
17.29%
6.76%
-43.03%
-13.66%
14.36%
-12.17%
-6.45%
-94.96%
-54.31%
15.04%
 
Cost Of Goods Sold
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
68.74
152.17
147.06
Gross Profit
8.81
7.11
6.66
11.69
13.54
11.84
13.48
14.41
216.93
473.09
396.47
GP Margin
99.93%
100%
100%
100%
100%
100%
100%
100%
75.94%
75.66%
72.94%
Total Expenditure
375.07
291.47
172.31
139.56
139.30
134.09
93.42
130.13
296.65
423.61
414.46
Power & Fuel Cost
-
0.56
0.30
0.26
0.00
0.00
0.00
1.63
19.37
33.56
31.50
% Of Sales
-
7.88%
4.50%
2.22%
0%
0%
0%
11.31%
6.78%
5.37%
5.80%
Employee Cost
-
24.15
20.82
18.99
18.62
21.02
18.53
17.41
36.49
61.27
52.17
% Of Sales
-
339.66%
312.61%
162.45%
137.52%
177.53%
137.46%
120.82%
12.77%
9.80%
9.60%
Manufacturing Exp.
-
249.18
145.00
115.15
115.72
106.53
71.16
103.25
147.09
144.07
153.86
% Of Sales
-
3504.64%
2177.18%
985.03%
854.65%
899.75%
527.89%
716.52%
51.49%
23.04%
28.31%
General & Admin Exp.
-
17.34
5.96
5.09
4.63
6.09
3.31
4.96
13.48
20.66
19.45
% Of Sales
-
243.88%
89.49%
43.54%
34.19%
51.44%
24.55%
34.42%
4.72%
3.30%
3.58%
Selling & Distn. Exp.
-
0.00
0.00
0.00
0.00
0.00
0.00
0.00
4.89
8.57
7.46
% Of Sales
-
0%
0%
0%
0%
0%
0%
0%
1.71%
1.37%
1.37%
Miscellaneous Exp.
-
0.24
0.23
0.08
0.33
0.46
0.41
2.88
6.59
3.31
7.46
% Of Sales
-
3.38%
3.45%
0.68%
2.44%
3.89%
3.04%
19.99%
2.31%
0.53%
0.54%
EBITDA
-366.25
-284.36
-165.65
-127.87
-125.76
-122.25
-79.94
-115.72
-10.98
201.65
129.07
EBITDA Margin
-4,152.49%
-3999.44%
-2487.24%
-1093.84%
-928.80%
-1032.52%
-593.03%
-803.05%
-3.84%
32.25%
23.75%
Other Income
20.85
13.93
10.90
21.13
8.45
1.60
7.75
14.04
27.25
23.27
21.09
Interest
0.64
0.31
0.17
0.30
0.41
0.67
0.94
0.55
1.91
4.63
5.68
Depreciation
6.41
5.61
5.82
6.50
6.54
4.39
4.35
4.17
14.20
24.76
21.41
PBT
-352.43
-276.34
-160.75
-113.54
-124.27
-125.71
-77.47
-106.40
0.16
195.53
123.07
Tax
0.00
0.00
0.00
-1.00
0.00
0.00
-5.32
-12.18
24.06
71.84
35.88
Tax Rate
0.00%
0.00%
0.00%
0.94%
0.00%
0.00%
6.87%
11.45%
15037.50%
36.74%
29.15%
PAT
-352.43
-276.34
-160.75
-105.08
-118.27
-122.00
-72.15
-94.22
-23.90
123.69
87.19
PAT before Minority Interest
-352.43
-276.34
-160.75
-105.08
-118.27
-122.00
-72.15
-94.22
-23.90
123.69
87.19
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-3,995.80%
-3886.64%
-2413.66%
-898.89%
-873.49%
-1030.41%
-535.24%
-653.85%
-8.37%
19.78%
16.04%
PAT Growth
0.00%
-
-
-
-
-
-
-
-
41.86%
 
EPS
-13.35
-10.47
-6.09
-3.98
-4.48
-4.62
-2.73
-3.57
-0.91
4.69
3.30

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
591.40
109.99
270.04
375.32
96.15
108.01
143.35
239.13
767.41
667.00
Share Capital
26.37
21.81
21.81
21.81
14.54
12.73
12.73
12.73
12.73
12.73
Total Reserves
407.81
86.90
248.23
353.51
81.61
58.36
130.62
226.40
754.68
654.27
Non-Current Liabilities
14.06
1.71
1.35
2.46
3.57
4.50
12.07
24.51
30.20
28.21
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.25
22.65
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.39
1.08
1.78
1.98
3.29
Long Term Provisions
1.92
1.71
1.35
1.88
2.00
1.73
1.72
1.49
3.69
2.84
Current Liabilities
18.75
23.49
13.52
105.03
102.21
109.81
120.03
156.97
225.83
208.05
Trade Payables
4.81
5.23
2.07
1.66
1.99
3.00
5.78
7.09
56.82
37.94
Other Current Liabilities
12.42
16.62
10.33
8.44
5.44
12.13
20.00
32.00
29.43
46.14
Short Term Borrowings
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
30.57
30.49
Short Term Provisions
1.52
1.64
1.12
94.92
94.78
94.68
94.25
117.88
109.01
93.49
Total Liabilities
624.21
135.19
284.91
482.81
201.93
222.32
275.45
420.61
1,023.44
903.26
Net Block
73.00
59.65
28.21
37.21
37.56
20.96
24.69
22.35
307.73
305.72
Gross Block
129.72
112.72
78.24
87.88
83.40
66.95
77.11
39.48
375.68
348.92
Accumulated Depreciation
56.73
53.06
50.03
50.67
45.83
45.99
52.42
17.13
67.95
43.19
Non Current Assets
77.51
59.71
28.23
137.32
41.44
25.74
115.95
22.37
349.61
322.10
Capital Work in Progress
3.60
0.01
0.00
0.00
3.55
4.77
0.00
0.02
24.74
9.72
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.07
0.07
Long Term Loans & Adv.
0.91
0.05
0.02
0.11
0.33
0.00
91.25
0.00
16.86
6.39
Other Non Current Assets
0.00
0.00
0.00
100.00
0.00
0.00
0.00
0.00
0.20
0.20
Current Assets
546.71
75.47
256.67
345.48
160.49
196.58
159.50
398.24
673.83
581.16
Current Investments
180.65
22.28
75.94
46.34
45.16
0.09
0.05
222.93
278.73
300.89
Inventories
0.10
0.24
0.71
0.00
0.02
0.14
0.00
0.00
139.47
92.51
Sundry Debtors
1.51
1.34
1.29
0.81
1.30
1.76
2.27
2.64
61.54
45.83
Cash & Bank
337.46
37.73
163.98
184.28
5.52
46.65
15.09
0.69
28.22
9.17
Other Current Assets
26.99
1.08
2.79
5.12
108.49
147.94
142.09
171.98
165.88
132.76
Short Term Loans & Adv.
22.35
12.82
11.97
108.93
99.78
141.25
140.72
169.20
115.53
99.87
Net Current Assets
527.96
51.99
243.16
240.46
58.28
86.77
39.48
241.27
448.00
373.11
Total Assets
624.22
135.18
284.90
482.80
201.93
222.32
275.45
420.61
1,023.44
903.26

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
-301.41
-154.10
-115.47
-115.98
-127.54
-96.02
-134.57
-52.61
69.94
109.17
PBT
-276.34
-160.75
-106.08
-118.27
-122.00
-77.47
-106.40
0.16
195.53
123.07
Adjustment
-5.98
-4.03
-22.46
-8.09
-1.09
-2.70
-8.26
-4.87
10.32
12.91
Changes in Working Capital
-18.33
10.07
6.89
11.48
-3.93
-14.70
-17.13
-32.98
-92.37
7.90
Cash after chg. in Working capital
-300.66
-154.71
-121.65
-114.88
-127.02
-94.88
-131.79
-37.70
113.47
143.88
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-0.76
0.61
6.18
-1.10
-0.52
-1.15
-2.78
-14.92
-43.54
-34.71
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-462.11
154.95
94.44
-247.81
-22.23
55.84
146.22
37.13
-0.61
-310.64
Net Fixed Assets
-20.59
-34.49
9.64
-0.93
-15.23
5.39
-37.61
360.92
-41.78
-26.29
Net Investments
-379.75
-60.70
-124.85
-102.35
-130.73
-53.26
117.43
21.74
-15.06
-342.87
Others
-61.77
250.14
209.65
-144.53
123.73
103.71
66.40
-345.53
56.23
58.52
Cash from Financing Activity
756.78
-0.76
-1.05
395.54
145.69
34.86
2.81
4.53
-52.07
-30.39
Net Cash Inflow / Outflow
-6.75
0.09
-22.09
31.75
-4.07
-5.33
14.45
-10.94
17.26
-231.86
Opening Cash & Equivalents
15.03
14.93
37.02
5.27
9.35
14.68
0.23
17.89
8.69
240.55
Closing Cash & Equivalent
8.28
15.03
14.93
37.02
5.27
9.35
14.68
0.23
25.95
8.69

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
16.46
4.99
12.38
17.21
6.09
5.15
11.26
18.79
60.29
52.40
ROA
-72.78%
-76.53%
-27.37%
-34.54%
-57.51%
-28.99%
-27.07%
-3.31%
12.84%
9.97%
ROE
-101.80%
-84.88%
-32.56%
-50.17%
-145.90%
-67.29%
-49.27%
-4.75%
17.25%
13.81%
ROCE
-78.71%
-84.51%
-32.78%
-49.94%
-117.81%
-60.09%
-54.67%
0.40%
26.01%
18.19%
Fixed Asset Turnover
0.06
0.07
0.14
0.16
0.16
0.19
0.25
1.38
1.73
1.62
Receivable days
72.97
71.91
32.67
28.38
47.15
54.60
62.22
41.00
31.34
33.32
Inventory Days
8.71
25.94
22.11
0.00
2.53
3.83
0.00
0.00
67.71
58.98
Payable days
0.00
0.00
0.00
0.00
0.00
0.00
18.53
39.04
38.79
33.17
Cash Conversion Cycle
81.68
97.84
54.79
28.38
49.67
58.43
43.70
1.96
60.26
59.13
Total Debt/Equity
0.00
0.00
0.00
0.00
0.01
0.02
0.01
0.01
0.04
0.11
Interest Cover
-904.16
-964.44
-354.37
-286.20
-181.00
-81.35
-191.96
1.08
43.25
22.65

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017

News Update:


  • Suven Life Sciences - Quarterly Results
    7th Aug 2026, 00:00 AM

    Read More
  • Suven Life Sciences gets nod to incorporate subsidiary in Singapore
    9th Jul 2026, 11:14 AM

    The new entity will be the Clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.